Maria Mizamtsidi1, Konstantinos Nastos2, Fausto Palazzo3, Vasilis Constantinides3, Roberto Dina4, Megan Farenden5, George Mastorakos6, Ioannis Vassiliou2, Maria Gazouli5. 1. Endocrine Surgery Unit, Second Department of Surgery, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece maria_mizamtsidi1@yahoo.gr. 2. Endocrine Surgery Unit, Second Department of Surgery, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece. 3. Department of Thyroid and Endocrine Surgery, Faculty of Medicine, Imperial College London, Hammersmith Hospital, London, U.K. 4. Department of Pathology, Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, U.K. 5. Laboratory of Biology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. 6. Unit of Endocrinology, Diabetes and Metabolism, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Abstract
BACKGROUND/AIM: Almost 15% of patients with sporadic primary hyperparathyroidism (sPHPT) present with multiple gland disease (MGD). The aim of this study was to investigate the potential role of two polymorphisms of the hsa-miR-30e, in sPHPT tumorigenesis. PATIENTS AND METHODS: One-hundred twenty sPHPT patients, 77 presenting a single adenoma and 43 with MGD, and 54 healthy controls were genotyped. The SNPs were identified using the allele-specific PCR methodology, while the hsa-miR-30e expression was analyzed by real-time quantitative reverse transcriptase PCR. RESULTS: Hsa-miR-30e expression was found to be significantly higher in patients with MGD compared to patients with single adenomas (p=0.0019), but no differences were found regarding specific genotype carriers. The genotype frequencies for ss178077483 and rs7556088 were significantly different between patients and healthy controls. CONCLUSION: Although the polymorphisms cannot be used as biomarkers for the differential diagnosis of MGD, hsa-miR-30e expression could potentially serve as a biomarker for this purpose. Copyright
BACKGROUND/AIM: Almost 15% of patients with sporadic primary hyperparathyroidism (sPHPT) present with multiple gland disease (MGD). The aim of this study was to investigate the potential role of two polymorphisms of the hsa-miR-30e, in sPHPT tumorigenesis. PATIENTS AND METHODS: One-hundred twenty sPHPT patients, 77 presenting a single adenoma and 43 with MGD, and 54 healthy controls were genotyped. The SNPs were identified using the allele-specific PCR methodology, while the hsa-miR-30e expression was analyzed by real-time quantitative reverse transcriptase PCR. RESULTS: Hsa-miR-30e expression was found to be significantly higher in patients with MGD compared to patients with single adenomas (p=0.0019), but no differences were found regarding specific genotype carriers. The genotype frequencies for ss178077483 and rs7556088 were significantly different between patients and healthy controls. CONCLUSION: Although the polymorphisms cannot be used as biomarkers for the differential diagnosis of MGD, hsa-miR-30e expression could potentially serve as a biomarker for this purpose. Copyright
Authors: David Velázquez-Fernández; Cecilia Laurell; Milena Saqui-Salces; Juan Pablo Pantoja; Fernando Candanedo-Gonzalez; Alfredo Reza-Albarrán; Armando Gamboa-Dominguez; Miguel F Herrera Journal: World J Surg Date: 2006-05 Impact factor: 3.352
Authors: S Uchino; S Noguchi; M Nagatomo; M Sato; H Yamashita; H Yamashita; S Watanabe; T Murakami; M Toda; S Wakiya; M Adachi Journal: Biomed Pharmacother Date: 2000-06 Impact factor: 6.529
Authors: Carl Morrison; William Farrar; Jeff Kneile; Nita Williams; Yiwen Liu-Stratton; Alan Bakaletz; Micheala A Aldred; Charis Eng Journal: Am J Pathol Date: 2004-08 Impact factor: 4.307
Authors: S Corbetta; V Vaira; V Guarnieri; A Scillitani; C Eller-Vainicher; S Ferrero; L Vicentini; I Chiodini; M Bisceglia; P Beck-Peccoz; S Bosari; A Spada Journal: Endocr Relat Cancer Date: 2010-02-18 Impact factor: 5.678
Authors: Natalia Bednarz; Krzysztof Błaut; Krzysztof Sworczak; Tomasz Oseka; Krzysztof P Bielawski Journal: Acta Biochim Pol Date: 2009-03-04 Impact factor: 2.149